Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.

MLA

Justin D Hoopes, et al. “Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus.” PLoS ONE, vol. 6, no. 12, Jan. 2011, p. e29778. EBSCOhost, https://doi.org/10.1371/journal.pone.0029778.

APA

Justin D Hoopes, Elizabeth M Driebe, Erin Kelley, David M Engelthaler, Paul S Keim, Alan S Perelson, Libin Rong, Gregory T Went, & Jack T Nguyen. (2011). Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS ONE, 6(12), e29778. https://doi.org/10.1371/journal.pone.0029778

Chicago

Justin D Hoopes, Elizabeth M Driebe, Erin Kelley, David M Engelthaler, Paul S Keim, Alan S Perelson, Libin Rong, Gregory T Went, and Jack T Nguyen. 2011. “Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus.” PLoS ONE 6 (12): e29778. doi:10.1371/journal.pone.0029778.